Ger­man gener­ic drug com­pa­ny Sta­da in ear­ly talks over pos­si­ble $11B sale, ex­ec con­firms

Spec­u­la­tion has been swirling in re­cent weeks over whether the Ger­man gener­ic drug com­pa­ny known as Sta­da might seek a sale worth about $11 bil­lion. CEO Pe­ter Gold­schmidt con­firmed the ru­mors to a Ger­man me­dia out­let on Tues­day but said he doesn’t ex­pect any­thing in the near term, a spokesper­son con­firmed.

Sta­da, bought by the in­vest­ment com­pa­ny Bain Cap­i­tal and the pri­vate eq­ui­ty firm Cin­ven for about $6 bil­lion in 2017, served up more strong quar­ter­ly growth, with the lat­est earn­ings up­date com­ing Tues­day. The com­pa­ny’s first half of the year showed strength, with sales up by 16% and earn­ings up by 30%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER